Weir 1995.

Methods	4‐week single‐blind placebo run‐in; inclusion criteria= mean supine DBP 95‐114 mm Hg during both of final 2 consecutive weeks of run‐in; 6‐week double‐blind treatment
Participants	Black and white patients reported in Weir 1995: Trandolapril 1 mg: n=51(33 males,18 females); mean age=58.3(11.4) years; baseline sitting SBP=154.8(15.0) mm Hg, DBP=100.3(4.3) mm Hg; Trandolapril 2 mg: n=53(36 males,17 females); mean age=57.3(10.9) years; baseline sitting SBP=151.9(13.1) mm Hg, DBP=101.7(5.1) mm Hg; Trandolapril 4 mg: n=53(28 males,25 females); mean age=53.0(12.4) years; baseline sitting SBP=147.6(13.8) mm Hg, DBP=99.9(4.4) mm Hg; Placebo: n=50(35 males,15 females); mean age=60.6(9.9) years; baseline SBP=152.1(14.9) mm Hg, DBP=100.9(5.0) mm Hg Only black patients reported in Weir 1998 (duplicate publication): Trandolapril 0.25 mg: n=23(12 males,11 females); mean age=48.6(12.7) years; baseline supine SBP=159.1(13.5) mm Hg, DBP=101.7(5.3) mm Hg; Trandolapril 0.5 mg: n=22(9 males,13 females); mean age=49.4(12.3) years; baseline supine SBP=152.1(11.7) mm Hg, DBP=101.6(4.9) mm Hg; Trandolapril 1 mg: n=23(7 males,16 females); mean age=52.7(11.1) years; baseline supine SBP=150.7(13.1) mm Hg, DBP=99.7(3.5) mm Hg (same patients as Weir 1995); Trandolapril 2 mg: n=22(10 males,12 females); mean age=53.0(10.2) years; baseline supine SBP=146.1(11.4) mm Hg, DBP=99.1(3.2) mm Hg (same patients as Weir 1995); Trandolapril 4 mg: n=60(28 males,32 females); mean age=53.6(10.8) years; baseline supine SBP=156.2(16.1) mm Hg, DBP=101.7(4.9) mm Hg (same patients as Weir 1995); Trandolapril 8 mg: n=38(19 males,19 females); mean age=55.3(11.9) years; baseline supine SBP=158.7(19.3) mm Hg, DBP=101.4(4.3) mm Hg; Trandolapril 12 mg: n=38(19 males,19 females); mean age=53.1(13.5) years; baseline supine SBP=153.0(12.4) mm Hg, DBP=100.9(4.1) mm Hg; Trandolapril 16 mg: n=36(15 males,21 females); mean age=54.4(12.2) years; baseline supine SBP=159.5(17.3) mm Hg, DBP=100.5(3.7) mm Hg; Placebo: n=60(27 males,33 females); mean age=53.5(10.0) years; baseline supine SBP=155.7(15.5) mm Hg, DBP=100.6(4.2) mm Hg
Interventions	Trandolapril 0.25 mg once daily (black patients only); Trandolapril 0.5 mg once daily (black patients only); Trandolapril 1 mg once daily (black and white patients); Trandolapril 2 mg once daily (black and white patients); Trandolapril 4 mg once daily (black and white patients); Trandolapril 8 mg once daily (black patients only); Trandolapril 12 mg once daily (black patients only); Trandolapril 16 mg once daily (black patients only); Placebo; administered between 8 AM and 10 AM
Outcomes	Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer (Trandolapril 1, 2, 4 mg treatment arms); Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer (Trandolapril 0.25, 0.5, 8, 12, 16 mg treatment arms); WDAE
Notes	Weir 1995: BP change and SE of change reported; calculated SD of change from N and SE of change; endpoint BP and SD not reported; SBP/DBP data from Table 2, p. 126; Jadad score=3; funding source= Knoll Pharma Weir 1998: BP change and SE of change reported for trandalopril groups; SBP SE of change in placebo group not reported; DBP SE of change in placebo group reported; imputed baseline SBP SE for SE of change; calculated SD of change from N and SE of change; endpoint BP and SD not reported; SBP/DBP data from Table 2, p. 191
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear